Current Report Filing (8-k)

false 0001800682 0001800682 2023-04-17 2023-04-17 0001800682 us-gaap:CommonClassAMember 2023-04-17 2023-04-17 0001800682 us-gaap:WarrantMember 2023-04-17 2023-04-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2023

 

 

CANO HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-39289		98-1524224
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

9725 NW 117th Avenue, Miami, Florida		33178
(Address of principal executive offices)		(Zip Code)

[phone]

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of each Class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.0001 par value per share		CANO		The New York Stock Exchange
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share		CANO WS		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

---

Item 8.01

Other Events.

On April 17, 2023, Cano Health, Inc. (the “Company”) issued a press release containing a letter to the Company’s shareholders from the Company’s board of directors (the “Board”).

Also on April 17, 2023, the Company issued a press release announcing the appointment of Solomon Trujillo as Chairman of the Board.

Copies of the press releases are filed hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference in their entirety.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.		Description
99.1		Press Release dated April 17, 2023.
99.2		Press Release dated April 17, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 17, 2023		CANO HEALTH, INC.
		By:		/s/ Brian D. Koppy
		Name:		Brian D. Koppy
		Title:		Chief Financial Officer